Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maxcyte (MXCT) Net Income (2020 - 2025)

Maxcyte (MXCT) has disclosed Net Income for 6 consecutive years, with -$9.6 million as the latest value for Q4 2025.

  • Quarterly Net Income rose 9.45% to -$9.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$44.6 million through Dec 2025, down 8.71% year-over-year, with the annual reading at -$44.6 million for FY2025, 8.71% down from the prior year.
  • Net Income for Q4 2025 was -$9.6 million at Maxcyte, up from -$12.4 million in the prior quarter.
  • The five-year high for Net Income was $9.3 million in Q4 2021, with the low at -$12.4 million in Q3 2025.
  • Average Net Income over 5 years is -$7.6 million, with a median of -$9.5 million recorded in 2024.
  • The sharpest move saw Net Income surged 57.12% in 2021, then plummeted 167.55% in 2023.
  • Over 5 years, Net Income stood at $9.3 million in 2021, then plummeted by 151.68% to -$4.8 million in 2022, then fell by 9.74% to -$5.3 million in 2023, then tumbled by 100.78% to -$10.6 million in 2024, then grew by 9.45% to -$9.6 million in 2025.
  • According to Business Quant data, Net Income over the past three periods came in at -$9.6 million, -$12.4 million, and -$12.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.